<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>

INVESTOR RELATIONS

Taking the Next Step - Adding in A Precision Cancer Therapeutic to the Platform - Upgrading to Buy

Maxim Group upgrades Trovagene from a "hold" position to a "buy" position based on PCM-075 (AML drug candidate) as the key driver of the company going forward

Apr 12, 2017


PDF
email print rss pdf